業績 論文

発表年
»2016年 »2015年 »2014年 »2013年
»2012年 »2011年  »2010年  »2009年  »2008年
2016年

■英文論文

  • Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, Onishi Y, Takahashi S, Uchida N, Eto T, Nakamae H, Yujiri T, Mori S, Nagamura-Inoue T, Suzuki R, Atsuta Y, Tanaka J. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the Adult ALL WG of the JSHCT. Bone Marrow Transplant. 51(1):43-50, 2016.
  • Arima N, Nakamura F, Yabe T, Tanaka J, Fuji S, Ohashi K, Fukuda T, Miyamura K, Iwato K, Eto T, Mori T, Kobayashi N, Hoshino T, Kato C, Kanamori H, Nakamae H, Atsuta Y, Morishima Y, Kanda Y. Influence of differently licensed KIR2DL1-positive natural killercells in transplant recipients with acute leukemia: a Japanese national registry study. BBMT 22(3):423-431, 2016.
  • Mori J, Ishiyama K, Yamaguchi T, Tanaka J, Uchida N, Kobayashi T, Fukuda T, Kanamori H, Miyamura K, Takahashi S, Eto T, Hirokawa H, Mori S, Nagamura T, Atsuta Y, Takami A. Outcomes of allogeneic hematopoietic cell transplantation for patients with biphenotypic acute leukemia. Annals of Hematol. 95:295-300, 2016.
  • Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T, Uike N, Hidaka M, Kobayashi R, Imamura M, Tanaka J, Ohashi K, Taniguchi S, Ikeda T, Eto T, Mori M, Yamaoka M, Ozawa K. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 103(2):243-250, 2016.
  • Mizutani M, Hara M, Fujita H, Aoki J, Kanamori H, Ohashi K, Usuki K, Fukuda T, Chou T, Tanaka J, Atsuta Y, Takami A. Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first complete remission. BMT 51(5):645-653, 2016.
  • Isono N, Imai Y, Watanabe A, Moriya K, Tamura H, Inokuchi K, Asano C, Masuda M, Shimura H, Mitsuhashi K, Kazama H, Sugimori H, Motoji T, Tanaka J. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. Leukemia and Lymphoma 57(9):2204-2207, 2016.
  • Mitsuhashi K, Kako S, Shigematsu A, Atsuta Y, Doki N, Fukuda T, Kanamori H, Onizuka M, Takahashi S, Ozawa Y, Kurokawa M, Inoue Y, Nagamura-Inoue T, Morishima Y, Mizuta S, Tanaka J. Comparison of cyclophosphamide combined with TBI, oral busulfan, or intravenous busulfan for allogeneic transplantation in adult patients with ALL. BBMT 22: 2194-2200, 2016.
  • Kogiso T, Hashimoto E, Ito T, Hara T, Ikarashi Y, Kodama K, Taniai M, Torii N, Yoshinaga K, Morita S, Takahashi Y, Tanaka J, Sakai S, Yamamoto M, Tokushige K. Successful Treatment of Ascites using a DenverR Peritoneovenous Shunt in a Patient with Paroxysmal Nocturnal Hemoglobinuria and Budd-Chiari syndrome. Intern Med. 55(20):2957-2963, 2016.
  • Mori N, Ohwashi M, Yoshinaga K, Okada M, Shiseki M, Tanaka J. Translocation (9;12)(q34.1;p13.?3) resulted in ETV6-ABL1 fusion in a patient with Philadelphia chromosome negative chronic myelogenous leukemia. Acta Haematologica 136:240?243, 2016.
  • Imai Y, Ohta E, Takeda S, Sunamura S, Ishibashi M, Tamura H, Wang Y, Deguchi A, Tanaka J, Maru Y, and Motoji T. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. JCI insight 1(5): e85061, 2016.
  • Tsukune Y, Sasaki M, Odajima T, Isoda A, Matsumoto M, Koike M, Tamura H, Moriya K, Ito S, Asahi M, Imai Y, Tanaka J, Handa H, Koiso H, Tanosaki S, Hua J, Hagihara M, Yahata Y, Suzuki S, Watanabe S, Sugimori H, Komatsu N. Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era. Ann Hematol. 95(9):1465-1472, 2016.
  • Arai Y, Kondo T, Shigematsu A, Tanaka J, Takahashi S, Kobayashi T, Uchida N, Onishi Y, Ishikawa J, Kanamori H, Sawa M, Yokota Y, Kouzai Y, Takanashi M, Ichinohe T, Atsuta Y, Mizuta S. High-dose cytarabine added to CY/TBI improves the prognosis of cord blood transplantation for acute lymphoblastic leukemia in adults: a retrospective cohort study. Bone Marrow Transplant. 2016 Dec;51(12):1636-1639.
  • Imai Y, Maru Y, Tanaka J. Clinical usage and mechanism of action for histone deacetylase inhibitors in the treatment of hematological malignancies. Cancer Science 107(11):1543-1549, 2016.

■和文論文

  • 志関雅幸、田中淳司:慢性難治性DICの診断と治療のポイントとは?
    Thrombosis Medicine 6:80-83, 2016.
  • 田中淳司:同種末梢血幹細胞移植片に含まれるーT細胞数・組成の意義
    血液内科 71: 351-355, 2016.
  • 田中淳司:ドナーリンパ球輸注DLI (Donor lymphocyte infusion)
    日本臨床 増刊号 白血病学 70-73, 2016. 日本臨床社
  • 田中淳司:Ph陰性急性リンパ性白血病の移植療法
    最新医学71巻11号: 91-100, 2016.
2015年

■英文論文

  • Aoki K, Ishikawa T, Ishiyama K, Aoki J, Itonaga H, Fukuda T, Kakihana K, Uchida N, Ueda Y, Eto T, Mori T, Kondo T, Iwato K, Morishima Y, Tanaka J, Atsuta Y, Miyazaki Y. Conditioning Regimen in Allogeneic Transplantation for Elderly Patients with Advanced Myelodysplastic Syndromes. Br J Haematol. 168:463-466, 2015.
  • Shiseki M, Masuda A, Yoshinaga K, Mori N, Okada M, Motoji T, Tanaka J. Identification of the SOX5 gene as a novel IGH-involved translocation partner in BCL2-negative follicular lymphoma with t(12;14)(p12.2;q32). Int J Hematol. 102(5):633-638, 2015.
  • Takahata M, Hashino S, Nishio M, Sugita J, Shigematsu A, Onozawa M, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T. Occurrence of adverse events caused by valganciclovir as preemptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration. Transpl Infect Dis. 17(6):810-815, 2015. doi: 10.1111/tid.12456.
  • Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, Onishi Y, Takahashi S, Uchida N, Eto T, Nakamae H, Yujiri T, Mori S, Nagamura-Inoue T, Suzuki R, Atsuta Y, Tanaka J.Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the Adult ALL WG of the JSHCT.Bone Marrow Transplant. 51(1):43-50, 2016. doi: 10.1038/bmt.2015.217.
  • Arima N, Nakamura F, Yabe T, Tanaka J, Fuji S, Ohashi K, Fukuda T, Miyamura K, Iwato K, Eto T, Mori T, Kobayashi N,Hoshino T, Kato C, Kanamori H, Nakamae H, Atsuta Y, Morishima Y, Kanda Y. Influence of differently licensed KIR2DL1-positive natural killercells in transplant recipients with acute leukemia: a Japanese national registry study. BBMT 22(3):423-431, 2016. doi: 10.1016/j.bbmt.2015.09.029.
  • Mori J, Ishiyama K, Yamaguchi T, Tanaka J, Uchida N,Kobayashi T, Fukuda T, Kanamori H, Miyamura K,Takahashi S, Eto1 T, Hirokawa H, Mori S, Nagamura T,Atsuta Y, Takami A. Outcomes of allogeneic hematopoietic cell transplantation for patients with biphenotypic acute leukemia. Annals of Hematol. 95:295-300, 2016.
  • Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T, Uike N, Hidaka M, Kobayashi R, Imamura M, Tanaka J, Ohashi K, Taniguchi S, Ikeda T, Eto T, Mori M, Yamaoka M, Ozawa K. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 103(2):243-250, 2016. doi: 10.1007/s12185-015-1915-9.
  • Mizutani M, Hara M, Fujita H, Aoki J, Kanamori H, Ohashi K, Usuki K, Fukuda T, Chou T, Tanaka J, Atsuta Y, Takami A. Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first complete remission. BMT (in press) doi: 10.1038/bmt.2015.349.
  • Isono N, Imai Y, Watanabe A, Moriya K, Tamura H, Inokuchi K, Asano C, Masuda M, Shimura H, Mitsuhashi K, Kazama H, Sugimori H, Motoji T, Tanaka J. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. Leukemia and Lymphoma (in press)
  • Ishihara H, Shimizu T, Unagami K, Hirai T, Toki D, Omoto K, Okumi M, Imai Y, Ishida H, and Tanabe K. Post-transplant lymphoproliferative disorder in kidney transplant recipients: a single-center experience in Japan. Ther Apher Dial in press
  • Uni M, Yoshimi A, Yamazaki S, Taoka K, Shinohara A, Nannya Y, Nakamura F, Kurokawa M. Comparison of garenoxacin with levofloxacin as antimicrobial prophylaxis in acute myeloid leukemia. Jpn J Clin Oncol. 2015 Aug;45(8):745-8. PMID: 25989991
  • Ueda R, Fuji S, Mori S, Hiramoto N, Hashimoto H, Tanaka T, Tada K, Kobayashi Y, Morikawa N, Shinohara A, Okinaka K, Maeshima AM, Kurosawa S, Kim SW, Yamashita T, Fukuda T. Characteristics and outcomes of patients diagnosed with norovirus gastroenteritis after allogeneic hematopoietic stem cell transplantation based on immunochromatography. Int J Hematol. 2015 Jul;102(1):121-8.PMID: 25930664
  • Higo T, Miyagaki T, Nakamura F, Shinohara A et al., Paraneoplastic pemphigus occurring after bendamustine and rituximab therapy for relapsed follicular lymphoma. Ann Hematol. 2015 Apr;94(4):683-5.
  • Takeshi Odajima, Minoko Takanashi, Hiroki Sugimori, Taiko Tanba, Kentaro Yoshinaga, Mutsuhiko Minami, Toshiko Motoji. Impact of Elevated Hemoglobin and Serum Protein on Vasovagal Reaction from Blood Donation. PLOS ONE 2016 Feb19:10.1371

■和文論文

  • 志関雅幸 (東京女医大 医 血液内科):臨床医が語る 新薬の治療・市場へのインパクト 慢性骨髄性白血病治療薬「ボスチニブ(ボシュリフ錠)」のインパクト, 月刊PHARM STAGE 巻:14 号:12 ページ:34-38
  • 今井陽一:AMLの遺伝子異常に基づいた治療戦略、臨床血液、56, 1932-1941, 2015.
  • 今井陽一:多発性骨髄腫のゲノム解析研究の進展、血液内科、70, 668-673, 2015.
  • 今井陽一:汎血球減少症例で見られた巨核球の形態異常 私のこの一枚(130)、血液フロンティア、25, 427-431, 2015.
2014年

■英文論文

  • Kobayashi R, Tanaka J, Hashino S, Ota S, Torimoto Y, Kakinoki Y, Yamamoto S, Kurosawa M, Hatakeyama N, Haseyama Y, Sakai H, Sato K, Fukuhara T. Etoposide-containing conditioning regimen reduces the occurrence of hemophagocytic lymphohistiocytosis after SCT. Bone Marrow Transplant. 49(2):254-257, 2014.
  • Hayase E, Fujimoto K, Mitsuhashi T, Hatanaka Y, Yoshida M, Takemura R, Iwasaki J, Shiratori S, Sugita J, Kondo T, Tanaka J, Imamura M, Matsuno Y, Teshima T. Epstein-barr virus-associated smooth muscle tumors after bone marrow transplantation. Transplantation. 2014 Jan 15;97(1):e1-5. doi: 10.1097/01.TP.0000437912.60638.23.
  • Shono Y, Shiratori S, Kosugi-Kanaya M, Ueha S, Sugita J, Shigematsu A, Kondo T, Hashimoto D, Fujimoto K, Endo T, Nishio M, Hashino S, Matsuno Y, Matsushima K, Tanaka J, Imamura M, Teshima T. Bone Marrow Graft-versus-Host Disease: Evaluation of Its Clinical Impact on Disrupted Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation.
    Biol Blood Marrow Transplant. 20(4):495-500, 2014.
  • Mizuta S, Matsuo K, Imai K, Nishiwaki S, kanamori H, Ohashi K, Fukuda T, Onishi Y, Miyamura K, Takahashi S, Onizuka M, Suzuki R, Atsuta Y, Morishima Y, Kato K, Sakamaki H, Tanaka J. Pre-transplant administration of imatinib for allogeneic hematopoietic stem cell transplantation in patients with BCR-ABL-positive acute lymphoblastic leukemia. Blood 123(15):2325-2332, 2014.
  • Sano H, Kobayashi R, Tanaka J, Hashino S, Ota S, Torimoto Y, Kakinoki Y, Yamamoto S, Kurosawa M, Hatakeyama N, Haseyama Y, Sakai H, Sato K, Fukuhara T. Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: a multicentre study. Br J Haematol. 165(6):786-792, 2014.
  • Kato H, Kawase T, Kako S, Mizuta S, Kurokawa M, Mori M, Ohashi K, Iwato K, Miyamura K, Hidaka M, Sakamaki H, Suzuki R, Morishima Y, Tanaka J. Analysis of outcomes following autologous transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia during the first complete remission. Haematologica. 99(11):e228-30, 2014. doi: 10.3324/haematol.2014.108712.
  • Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y, Morishima Y, Fukuda T, Miyazaki Y, Nakamae H, Tanaka J, Atsuta Y,1 Kanamori H. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A retrospective analysis by the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant.20(11):1785-1790,2014.
  • Takahata M, Hashino S, Onozawa M, Shigematsu A, Sugita J, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T. Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transpl Infect Dis. 2014 16(5):797-801.
  • Kanda J, Fuji S, Kato S, Takami A, Tanaka J, Miyamura K, Ohashi K, Takahiro Fukuda2, Ozawa Y, Kanamori H, Eto T, Kobayashi N, Iwato K, Morishima Y, Sakamaki H, Atsuta Y, Kanda Y. Decision Analysis for Donor 1 Selection in Stem Cell Transplantation ?2 HLA-8/8 Allele-Matched Unrelated Donor vs. HLA-1 AG Mismatched Related Donor. Blood Cancer J. 2014. Dec 5;4:e263. 1-9. doi: 10.1038/bcj.2014.85.
  • Shiozaki H, Yoshinaga K, Kondo T, Imai Y, Shiseki M, Mori N, Teramura M, Motoji T / Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source. - Bone Marrow Transplant 49: (102-109), 2014
  • Shinohara A, Imai Y, Nakagawa M, Takahashi T, Ichikawa M, Kurokawa M / Intracellular reactive oxygen species mark and influence the megakaryocyte-erythrocyte progenitor fate of common myeloid progenitors. - Stem Cells 32: (548-557), 2014
  • Kazama H, Teramura M, Kurihara K, Yoshinaga K, Kato T, Motoji T. Peroxiredoxin 2 expression is increased in neutrophils of patients with refractory cytopenia with multilineage dysplasia. Br J Haematol. 166: 720-728, 2014
  • Tochihara M, Kasai M, Katsumata Y, Sato E, Ishiguro N, Kazama H, Sugimoto N, Ichida H, Kawaguchi Y, YamanakaH. Erythematosus plaques with macrophage infi ltration as an initial manifestation of macrophage activation syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol, DOI: 10.3109/14397595.2014.932042
  • Takaoka K, Nannya Y, Shinohara A et al., A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma., Ann Hematol. 2014 Oct;93(10):1637-44.
  • Nasu R, Nannya Y, Shinohara A et al., Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases., Annals of Hematology., 93(7), 1215-23, 2014
  • Nannya Y, Shinohara A et al., Serial profile of vitamins and trace elements during the acute phase of allogeneic stem cell transplantation., Biology of Blood and Marrow Transplantation., 20(3), 430-4, 2014
  • Hiramoto N, Kurosawa S, Tajima K, Okinaka K, Tada K, Kobayashi Y, Shinohara A et al. , Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients., Europian Journal of Haematology, 92(2), 137-46, 2014

■和文論文

  • 田中淳司:多発性骨髄腫, 耳鼻咽喉科・頭頚部外科86:258-262, 2014
  • 田中淳司:同種造血幹細胞移植の発展, 東京女子医科大学雑誌84:87-93, 2014.
  • 田中淳司:造血細胞移植の移植免疫学?NK細胞の役割, 臨床血液55:2142-2151, 2014.
  • 田中淳司:急性リンパ性白血病に対する同種造血幹細胞移植の適応と有効性, 血液内科 69:616-623, 2014.
  • 石田高司、伊藤旭、戸倉新樹、田中淳司、鵜池直邦、飛内賢正、塚崎邦弘:血液内科医・皮膚科医のための統合ATL診療ガイドライン解説書2014, 臨床血液55:2257-2261, 2014.
  • 倉田 美穂, 柳澤 昌実, 熱田 由子, 坂巻 壽, 加藤 剛二, 一戸 辰夫, 田中 淳司, 廣川 誠, 足立 壮一, 井上 雅美, 菊池 陽, 矢部 普正, 河 敬世, 澤田 明久, 森 慎一郎, 森島 泰雄, 加藤 俊一, 長村 登紀子, 松本 加代子, 鈴木 律朗, 中尾 眞二, 高梨 美乃子, 小寺 良尚, 岡本 真一郎:日本における造血細胞移植 ―2013年度全国調査より―, 臨床血液55:2381-2399, 2014.
  • 早瀬英子、杉田純一、藤本勝也、江端 浩、山川知宏、吉田美穂、竹村 龍、岩崎純子、高橋正二郎、白鳥 聡一、 近藤 健、田中 淳司、豊嶋崇徳:ビンクリスチンによる麻痺性イレウスに引き続きposterior reversible encephalopathy syndromeを発症したT細胞性リンパ芽球性リンパ腫 臨床血液 55(2): 249-253, 2014
  • 志村華絵、今井陽一、田中 淳司:腹腔内巨大腫瘍で発症した腎移植後リンパ増殖性疾患 血液フロンテイア 24(1): 5-10, 2014
  • 今井陽一、太田瑛里/ 多発性骨髄腫発生病理とmixed-lineage leukemia (MLL) タンパク - 日本臨牀 72: (1047-1051), 2014
  • 森直樹: MYD88遺伝子変異をめぐって. 腫瘍内科 14(6) 604-610, 2014
  • 森直樹: 原発性マクログロブリン血症の新規遺伝子異常. 血液フロンテイア 24(12) 84-88, 2014
  • 篠原明仁ほか、「Ph陽性急性リンパ性白血病に対する同種造血幹細胞移植前後のチロシンキナーゼ阻害薬の意義」、血液内科、69巻5号、P624、2014年
  • 篠原明仁ほか、「約6カ月の経過で進行した四肢遠位の感覚異常と下肢優位の筋力低下を呈する高ガンマグロブリン血症の60歳代男性」、レジデントノート、16巻3号、P578、2014年
  • 篠原明仁ほか、「同種造血幹細胞移植」、耳鼻咽喉部科・頭頸部外科、86巻3号、P405、2014年
  • 篠原明仁ほか、「高齢者骨髄異形成症候群に対する同種造血幹細胞移植」、血液内科、68巻3号、P405、2014年
2013年

■英文論文

  • Tanaka J, Kanamori H, Nishiwaki S, Ohashi K, Taniguchi S, Eto T, Nakamae H, Minagawa K, Miyamura K, Sakamaki H, Morishima Y, Kato K, Suzuki R, Nishimoto N, Oba K, Masauzi N. Reduced-intensity versus myeloablative conditioning allogeneic hematopoietic stem cell transplantation for patients aged over 45 years with acute lymphoblastic leukemia (ALL) in remission: A study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Bone Marrow Transplant. 48:1389-1394, 2013.
  • Nishiwaki S, Miyamura K, Ohashi K, Kurokawa M, Taniguchi S, Fukuda T, Ikegame K, Takahashi S, Mori T, Imai K, Iida H, Hidaka M, Sakamaki H, Morisima Y, Kato K, Suzuki R, Tanaka J. Impact of donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Ann Oncology. 24:1594-1602, 2013.
  • Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, Taniguchi S, Miyamura K, Takahashi S, Eto T, Ogawa H, Kurokawa M, Tanaka J, Kawa K, Kato K, Suzuki R, Morishima Y, Sakamaki H, Fukuda T. Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia. Bone Marrow Transplant. 48:1198-1204, 2013.
  • Nishiwaki S, Atsuta Y, Tanaka J. Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative acute lymphoblastic leukemia: What should we choose when no HLA-matched related donor is available? Bone Marrow Transplant. 48:1369-1376, 2013.
  • Mitsuhashi K, Momose M, Masuda A, Tsunemi Y, Motoji T: Positron emission tomography revealed diffuse involvement of the lower legs and occult extracutaneous lesions in subcutaneous panniculitis-like T-cell lymphoma. Clin Nucl Med 38: 209-211, 2013
  • Shimura H, Imai Y, Ieko M, Shiseki M, Mori N, Teramura M, Motoji T: Transient lupus anticoagulant with a prolonged activated partial thromboplastin time secondary to cytomegalovirus-related infectious mononucleosis. Ann Hematol 92: 143-144, 2013
  • Wakao H, Yoshikiyo K, Koshimizu U, Furukawa T, Enomoto K, Matsunaga T, Tanaka T, Yasutomi Y, Yamada T, Minakami H, Tanaka J, Oda A, Sasaki T, Wakao R, Lantz O, Udagawa T, Sekiya Y, Higuchi K, Harada N, Nishimura K, Ohtaka M, Nakanishi M, Fujita H. Expansion of Functional Human Mucosal-Associated Invariant T Cells via Reprogramming to Pluripotency and Redifferentiation. Cell Stem Cell. 12(5): 546-558, 2013.
  • Kanda J, Ichinohe T, Kato S, Uchida N, Terakura S, Fukuda T, Hidaka M, Ueda Y, Kondo T, Taniguchi S, Takahashi S, Nagamura-Inoue T, Tanaka J, Atsuta Y, Miyamura K, Kanda Y. Unrelated cord blood transplantation vs. related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction. Leukemia 27(2): 286-294, 2013.
  • Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, Taniguchi S, Miyamura K, Takahashi S, Eto T, Ogawa H, Kurokawa M, Morishima Y, Tanaka J, Sakamaki H, Fukuda T. Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome. Bone Marrow Transplant 48(4): 529-536, 2013.
  • Imahashi N, Suzuki R, Fukuda T, Kakihana K, Kanamori H, Eto T, Mori T, Kobayashi N, Iwato K, Sakura T, Ikegame K, Kurokawa M, Kondo T, Iida H, Sakamaki H, Tanaka J, Kawa K, Morishima Y, Atsuta Y, Miyamura K. Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant 48(1): 56-62, 2013.
  • Kanamori H, Mizuta S, Kako S, Kato H, Nishiwaki S, Imai K, Shigematsu A, Nakamae H, Tanaka M, Ikegame K, Yujiri T, Fukuda T, Minagawa K, Eto T, Nagamura-Inoue T, Morishima Y, Suzuki R, Sakamaki H, Tanaka J. Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 48:1513-1518, 2013.
  • Tanaka J, Morishima Y, Takahashi Y, Yabe T, Oba K, Takahashi S, Taniguchi S, Ogawa H, Onishi Y, Miyamura K, Kanamori H, Aotsuka N, Kato K, Kato S, Atsuta Y, Kanda Y. Effects of KIR-ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission. Blood Cancer Journal 3, e164; 2013. doi:10.1038/bcj.2013.62.
  • Mori N, Ohwashi M, Yoshinaga K, Mitsuhashi K, Tanaka N, Teramura M, Okada M, Shiseki M, Tanaka J, Motoji T. L265P mutation of the MYD88 gene is frequent in Waldenstrom's macroglobulinemia and its absence in myeloma. PLoS One5;8(11):e80088. 2013, doi: 10.1371.
  • Shinohara A, Yoshiki Y, Masamoto Y et al., Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropenia in patients with hematological malignancies., Leukeimia Lymphoma, 54(4), 794-8、2013
  • Toya T, Shinohara A et al., A case of Schizophyllum commune sinusitis following unrelated cord blood transplantation for acute lymphoblastic leukemia., International Journal of Hematology, 98(2), 261-3, 2013
  • Watanabe-Okochi N, Yoshimi A, Sato T, Ikeda T, Kumano K, Taoka K, Satoh Y, Shinohara A et al., The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model., Blood, 121(20), 4142-55, 2013

■和文論文

  • 吉永健太郎, 泉二登志子: 遺伝性対熱奇形赤血球症. 日本臨床別冊血液症候群第2版I, 188-191, 2013
  • 吉永健太郎, 泉二登志子: Rhnull症. 日本臨床別冊血液症候群第2版I, 194-197, 2013
  • 三橋健次郎, 森直樹, 泉二登志子, 好中球アクチン異常症. 日本臨床別冊血液症候群第2版II, 85-88, 2013
  • 田中紀奈, 森直樹, 泉二登志子: Job症候群. 日本臨床別冊血液症候群第2版II 89-92, 2013
  • 森直樹, 泉二登志子: なまけもの白血病症候群. 日本臨床別冊血液症候群第2版II 93-94, 2013
  • 田中淳司: Lymphoid myelofibrosis. 日本臨床別冊血液症候群第2版III 108-109, 2013
  • 田中淳司: Neutrophilic myelofibrosis. 日本臨床別冊血液症候群第2版III 110-111, 2013
  • 泉二登志子・王 艶華: 急性白血病の薬剤耐性とABCトランスポーター. 東京女子医科大学雑誌83: E451-E457, 2013
  • 王 艶華・泉二登志子: 白血病細胞におけるWnt/β-カテニンシグナル伝達経路と薬剤耐性. 東京女子医科大学雑誌83: E458-E464, 2013
  • 今井陽一・泉二登志子: 多発性骨髄腫の治療抵抗性獲得において接着分子が果たす役割. 東京女子医科大学雑誌83: E465-E469, 2013
  • 増田道彦・浅野千尋: 後天性赤芽球癆の病態と治療. 東京女子医科大学雑誌83: E485-E488, 2013
  • 寺村正尚: 再生不良性貧血に対するウサギ抗胸腺細胞グロブリン療法の現状. 東京女子医科大学雑誌83: E489-E495, 2013
  • 志関雅幸: 骨髄異形成症候群における20番染色体長腕欠失の臨床的、生物学的意義. 東京女子医科大学雑誌83: E496-E501, 2013
  • 森 直樹: 後天性血友病A:第Ⅷ因子インヒビター. 東京女子医科大学雑誌83: E508-E511, 2013
  • 山田 修: Telomeres and Telomerase in Hematology. 東京女子医科大学雑誌83: E520-E538
  • 岡田美智子・宇佐美明美・岡嶋 香・三浦裕子・兒玉聖子・志村華絵・田中紀奈・三橋健次郎・石山みどり・風間啓至・吉永健太郎・今井陽一・志関雅幸・森 直樹・寺村正尚・泉二登志子: 急性骨髄性白血病の病型分類と染色体異常―東京女子医科大学病院血液内科の過去28年間300症例における解析. 東京女子医科大学雑誌83: E539-E547, 2013
  • 田中紀奈・森 直樹・榎本有希・渡邉 彩・石森紀子・丁  曄・志村華絵・兒玉聖子・三橋健次郎・石山みどり・風間啓至・吉永健太郎・今井陽一・志関雅幸・山田 修・寺村正尚・泉二登志子: 成人急性骨髄性白血病の成績:単施設における後方視的検討. 東京女子医科大学雑誌83: E548-E555, 2013
  • 志村華絵・森 直樹・岡田美智子・榎本有希・渡邉 彩・石森紀子・丁  曄・兒玉聖子・田中紀奈・三橋健次郎・石山みどり・風間啓至・吉永健太郎・今井陽一・志関雅幸・寺村正尚・泉二登志子: 当科での急性リンパ性白血病の治療成績. 東京女子医科大学雑誌83: E556-E562, 2013
  • 風間啓至・寺村正尚・榎本有希・渡邉 彩・石森紀子・丁  曄・志村華絵・兒玉聖子・田中紀奈・三橋健次郎・石山みどり・吉永健太郎・今井陽一・志関雅幸・森 直樹・泉二登志子: 濾胞性リンパ腫に対するリツキシマブ併用化学療法の当科における成績. 東京女子医科大学雑誌83: E563-E568
  • 三橋健次郎・志関雅幸・榎本有希・渡邉 彩・石森紀子・丁  曄・志村華絵・兒玉聖子・田中紀奈・石山みどり・風間啓至・吉永健太郎・今井陽一・森 直樹・寺村正尚・泉二登志子: リツキシマブ併用化学療法を受けたびまん性大細胞型B細胞リンパ腫における改訂国際予後指標の有用性. 東京女子医科大学雑誌 83: E569-E575
  • 岡村隆光・増田道彦・寺村正尚・泉二登志子: Activation of Retinoic Acid Receptor α is Important for the Anti-myeloma Effect of Retinoids: New Therapeutic Approach Using Receptor Selective Retinoids for Multiple Myeloma. 東京女子医科大学雑誌 83: E576-E584
  • 吉永健太郎・榎本有希・渡邉 彩・石森紀子・丁  曄・志村華絵・兒玉聖子・田中紀奈・浅野千尋・三橋健次郎・石山みどり・近藤年昭・安並 毅・風間啓至・岡村隆光・今井陽一・志関雅幸・森 直樹・山田 修・寺村正尚・増田道彦・泉二登志子: 東京女子医科大学病院における造血幹細胞移植の後方視的解析. 東京女子医科大学雑誌 83: E585-E593
  • 石山みどり・寺村正尚・岡村隆光・志村華絵・兒玉聖子・田中紀奈・三橋健次郎・風間啓至・吉永健太郎・今井陽一・志関雅幸・森 直樹・泉二登志子: 原発性骨髄線維症に合併した大量腹水に対して腹腔静脈シャントが著効した1例. 東京女子医科大学雑誌 83: E594-E598
  • 石森紀子・兒玉聖子・浅野千尋・増田道彦: t(6;11)(q27;q23)の染色体異常を伴う高齢者急性骨髄性白血病の1例. 東京女子医科大学雑誌 83: E599-E603
  • 兒玉聖子・浅野千尋・増田道彦: 非ホジキンリンパ腫の治療後に急性巨核芽球性白血病として発症した治療関連急性骨髄性白血病. 東京女子医科大学雑誌 83: E604-E607
  • 榎本有希・兒玉聖子・浅野千尋・増田道彦: 多発病変を認めた両側副腎原発非ホジキンリンパ腫(MALT型)の1例. 東京女子医科大学雑誌 83: E612-E616
  • 本村小百合・村井善郎・小林祥子・日台裕子・堤  久・寺村正尚・泉二登志子: 血球貪食症候群で発症し抗利尿ホルモン不適合分泌症候群を呈した血管内大細胞型B細胞リンパ腫. 東京女子医科大学雑誌 83: E617-E621
  • 安並 毅・吉永健太郎・風間啓至・志関雅幸・森 直樹・寺村正尚・泉二登志子: 中枢性過換気を来たした中枢神経原発悪性リンパ腫. 東京女子医科大学雑誌 83: E622-E627
  • 丁  曄・吉永健太郎・丸山正隆・今井陽一・志関正幸・森 直樹・増田昭博・寺村正尚・泉二登志子: Regression of Rectal Mucosa-associated Lymphoid Tissue (MALT) Lymphoma after Helicobacter pylori Eradication. 東京女子医科大学雑誌 83: E628-E632
  • 渡邉 彩・今井陽一・志村華絵・田中紀奈・三橋健次郎・風間啓至・志関雅幸・森 直樹・寺村正尚・泉二登志子: びまん性大細胞型B細胞リンパ腫(DLBCL)に、M蛋白血症と免疫性血小板減少症(ITP)を併発し、化学療法により血小板数の増加が得られた1例. 東京女子医科大学雑誌 83: E633-E637
  • 塩崎宏子・岡村隆光・田嶋 強・石山みどり・吉永健太郎・志関雅幸・森 直樹・寺村正尚・泉二登志子: 急性リンパ性白血病に合併した腸管嚢胞様気腫症の1例 : 血液疾患に合併する同症についての文献的考察を加えて. 東京女子医科大学雑誌 83: E638-E642
  • 平井由児・菊池 賢・杉田 隆・池田玲子・後藤亜江子・鶴岡直樹・澤田達男・大貫恭正・玉置 淳・戸塚恭一・泉二登志子: 同時に莢膜産生性の異なる2種類のC. neoformansが検出された肺クリプトコッカス症. 東京女子医科大学雑誌 83: E643-E648
  • 今井陽一:がんの最新治療 各論(5)多発性骨髄腫. 東京女子医科大学雑誌 in press
  • 篠原明仁ほか、「AML第 1 寛解期における治療選択:同種造血幹細胞移植の意義」、血液内科、67巻5号、P573、2013年
  • 篠原明仁ほか、「MDSに対する同種造血幹細胞移植前メチル化阻害薬投与の意義」、血液内科、67巻3号、P364、2013年
  • 篠原明仁ほか、「再生不良性貧血」、内科、112巻2号、P275、2013年
  • 篠原明仁ほか、「Scott症候群」、日本臨牀、血液症候群(第2版)II、P440、2013年
  • Watanabe-Okochi N, Yoshimi A, Sato T, Ikeda T, Kumano K, Taoka K, Satoh Y, Shinohara A et al., The shortest isoform of C/EBPβ, Liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model, 臨床血液, 54巻8号, 749-58, 2013年
2012年

■英文論文

  • Tanaka J, Sugita J, Shiratori S, Shigematsu A, Imamura M. Dasatinib enhances the expansion of CD56+CD3- NK cells from cord blood. Blood 119: 6175-6176, 2012.
  • Tanaka J, Sugita J, Shiratori S, Shigematsu A, Asanuma S, Fujimoto K, Nishio M, Kondo T, Imamura M. Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells. Leukemia 26: 1149-1152, 2012.
  • Kanda J, Saji H, Fukuda T, Kobayashi T, Miyamura K, Eto T, Kurokawa M, Kanamori H, Mori T, Hidaka M, Iwato K, Yoshida T, Sakamaki H, Tanaka J, Kawa K, Morishima Y, Suzuki R, Atsuta Y, Kanda Y. Related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction and HLA 8/8-allele-matched unrelated transplantation: A nationwide retrospective study. Blood 119: 2409-2416, 2012.
  • Kashiwazaki H, Matsushita T, Sugita J, Shigematsu A, Kasashi K, Yamazaki Y, Kanehira T, Yamamoto S, Kondo T, Endo T, Tanaka J, Hashino S, Nishio M, Imamura M, Kitagawa Y, Inoue N. Professional oral health care reduces oral mucositis and febrile neutropenia in patients treated with allogeneic bone marrow transplantation. Support Care Cancer. 20: 367-373,2012.
  • Sugita J, Matsushita T, Kashiwazaki H, Kosugi M, Takahashi S, Wakasa K, Shiratori S, Ibata M, Shono Y, Shigematsu A, Obara M, Fujimoto K, Endo T, Nishio M, Kondo T, Hashino S, Tanaka J, Asaka M, Imamura M. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD. Bone Marrow Transplant. 47: 258-264.2012.
  • Kashiwazaki H, Matsushita T, Sugita J, Shigematsu A, Kasashi K, Yamazaki Y, Kanehira T, Kondo T, Endo T, Tanaka J, Hashino S, Nishio M, Imamura M, Kitagawa Y, Inoue N. A comparison of oral mucositis in allogeneic hematopoietic stem cell transplantation between conventional and reduced-intensity regimens. Support Care Cancer. 20: 933-939, 2012.
  • Tsutsumi Y, Ogasawara R, Ito S, Sasaki J, Morita A, Senoo N, Murata N, Tanaka J, Asaka M, Imamura M.Retrospective analysis of an efficient peripheral blood stem cell collection and the relation between infused cell dose and clinical outcome in patients with malignant lymphoma and multiple myeloma. Int J Lab Hematol. 34: 403-409, 2012.
  • Tsutsumi Y, Ogasawara R, Miyashita N, Tanaka J, Asaka M, Imamura M. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine. Int J Hematol. 95: 588-591, 2012
  • Toubai T, Tanaka J, Paczesny S, Shono Y, Reddy P, Imamura M. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD)- Are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (allo-HCT) Curr Stem Cell Res Ther. 7: 229-239, 2012.
  • Matsukawa T, Goto H, Takahashi K, Asanuma S, Yasumoto A, Takahata M, Shigematsu A, Endo T, Tanaka J, Hashino S, Tanaka S, Imamura M. A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations. Int J Hematol 95:217-222, 2012.
  • Matsukawa T, Goto H, Takahashi K, Asanuma S, Yasumoto A, Takahata M, Shigematsu A, Endo T, Tanaka J, Hashino S, Tanaka S, Imamura M. A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations. Int J Hematol 95(2): 217-222, 2012.
  • Matsukawa T, Shigematsu A, Hayasaka K, Fujisawa S, Asanuma S, Yasumoto A, Goto H, Takahata M, Endo T, Tanaka J, Hashino S, Shimizu C, Imamura M.Chimerism analyses by sex-chromosome analysis confused relapse with donor cell leukemia after sex-mismatched allo-SCT. Bone Marrow Transplant 47(12): 1583-1584, 2012.
  • Okada K, Higashiyama A, Takahata M, Onozawa M, Kahata K, Ando S, Tanaka J, Hashino S, Imamura M. Complete remission following chemotherapy with low-dose cytosine arabinoside and macrophage colony-stimulating factor/granulocyte colony-stimulating factor in a patient with relapsed acute myeloid leukemia after stem cell transplantation. Intern Med 51(20): 2937-2941, 2012.
  • Yoshimi M, Goyama S, Kawazu M, Nakagawa M, Ichikawa M, Imai Y, Kumano K, Asai T, Mulloy JC, Kraft AS, Takahashi T, Shirafuji N, and Kurokawa M. Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. European Journal of Immunology 42: 1044-1050, 2012.
  • Taoka K, Kumano K, Nakamura F, Hosoi M, Goyama S, Imai Y, Hangaishi A, Kurokawa M. The effect of iron overload and chelation on erythroid differentiation. International Journal of Hematology 95: 149-159, 2012.
  • Ainoda Y, Hirai Y, Fujita T, Isoda N, Totsuka K: Analysis of clinical features of non-HIV Pneumocystis jirovecii pneumonia. J Infect Chemother 18: 722-728, 2012
  • Hirai Y, Yamamoto A, Yaguchi A, Totsuka K: Lockjaw occurring after attending a small kitchen garden. Intern Med 51: 2991, 2012
  • Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, Yamazaki H, Tauchi T, Imai K, Mori N, Yagasaki F, Maeda Y, Usui N, Miyazaki Y, Miyamura K, Kiyoi H, Ohtake S, Naoe T; Japan Adult Leukemia Study Group. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci 103: 1071-1078, 2012
  • Ogata K, Kakumoto K, Matsuda A, Tohyama K, Tamura H, Ueda Y, Kurokawa M, Takeuchi J, Shibayama H, Emi N, Motoji T, Miyazaki Y, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F: Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study. Leuk Res 36: 1229-1236, 2012
  • Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, Usui N, Okamoto S, Ohe Y, Ohtake S, Kitamura K, Yamamoto M, Teshima H, Motoji T, Tamaki T, Sawada K, Ohyashiki K: Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 97: 903-906, 2012
  • Ueda Y, Mizutani C, Nannya Y, Kurokawa M, Kobayashi S, Takeuchi J, Tamura H, Ogata K, Dan K, Shibayama H, Kanakura Y, Niimi K, Sasaki K, Watanabe M, Emi N, Teramura M, Motoji T, Kida M, Usuki K, Takada S, Sakura T, Ito Y, Ohyashiki K, Ogawa H, Suzuki T, Ozawa K, Imai K, Kasai M, Hata T, Miyazaki Y, Morita Y, Kanamaru A, Matsuda A, Tohyama K, Koga D, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F: Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. Leuk Lymphoma 2012 [Epub ahead of print]
  • Hirai Y, Yoshihara T, Motoji T, Totsuka K: Facial-oropharyngeal Kaposi Sarcoma in a HIV-seropositive man. Intern Med 51: 2989-2990, 2012
  • Takanashi M, Odajima T, Aota S, Sudoh M, Yamaga Y, Ono Y, Yoshinaga K, Motoji T, Matsuzaki K, Satake M, Sugimori H, Nakajima K: Risk factor analysis of vasovagal reaction from blood donation. Transfus Apher Sci 47: 319-325, 2012.
  • Okada M, Suto Y, Hirai M, Shiseki M, Usami A, Okajima K, Teramura M, Mori N, Motoji T: Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies. Cancer Genet 205: 18-24, 2012.
  • Tsuji K, Wang YH, Takanashi M, Odajima T, Lee GA, Sugimori H, Motoji T. Overexpression of lung resistance-related protein and P-glycoprotein and response to induction chemotherapy in acute myelogenous leukemia. Hematol Rep 4: e18, 2012.
  • Mori N, Totsuka K, Ishimori N, Yoshinaga K, Teramura M, Noguchi S, Oda H, Motoji T: Acquired Hemophilia A in a Patient with Essential Thrombocythemia. Acta Haematol 127: 170-172, 2012
  • Shimura H, Mori N, Wang YH, Okada M, Motoji T: Aberrant methylation and decreased expression of the RIZ1 gene are frequent in adult acute lymphoblastic leukemia of T cell phenotype. Leuk Lymphoma 53: 1599-1609, 2012
  • Mitsuhashi K, Ishiyama M, Imai Y, Shiseki M, Mori N, Teramura M, Seshimo A, Motoji T: Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy. Br J Haematol 158: 798-800, 2012
  • Kazama H, Teramura M, Yoshinaga K, Masuda A, Motoji T: Long-term remission of primary bone marrow diffuse large B-cell lymphoma treated with high-dose chemotherapy rescued by in vivo rituximab-purged autologous stem cells. Case Report Med 2012: 957063, 2012.
  • Teramura M, Ishiyama M, Kazama H, Yoshinaga K, Shiseki M, Mori N, Motoji T: Comparison of High-Dose Dexamethasone and Prednisone for Initial Treatment of Adult Primary Immune Thrombocytopenia. Open J Blood Diseases 2: 85-89, 2012

■和文論文

  • 田中淳司: Ph陰性ALLにおける微小残存病変の検出法とその意義. 血液内科 65: 670-674, 2012.
  • 政氏伸夫, 田中淳司, 笠井正晴, 小笠原正浩, 小林直樹, 木山善雄, 土井みなみ, 福井彩佳, 藤本奈緒, 山田実早希, 三輪佳子, 小林正伸, 今村雅寛: PBSC採取量予測における末梢血CD34陽性細胞上の接着分子発現の評価方法の検討. Cytometry Reaearch 22: 27-31, 2012.
  • 高畑むつみ, 橋野聡, 藤本勝也, 遠藤知之, 小林直樹, 黒澤光俊, 岩崎 博, 三宅高義, 幸田久平, 前川 勲, 笹川 裕, 堤 豊, 宮城島拓人, 田中淳司, 今村雅寛, 豊嶋崇徳: 特発性血小板減少性紫斑病治療におけるセファランチン大量療法の有用性 ~後方視的多施設共同研究~. 臨床血液 53(12): 1983-90, 2012
  • 田中紀奈, 吉永健太郎, 浅野千尋, 風間啓至, 岡村隆光, 志関雅幸, 森直樹, 寺村正尚, 日下部きよ子, 坂井修二, 泉二登志子: POEMS症候群の病変検出における18F-FDG PET/CT の有用性. 臨床血液 53: 2013-2017, 2012
  • 志村華絵, 今井陽一, 石山みどり, 吉永健太郎, 志関雅幸, 森直樹, 寺村正尚, 泉二登志子: 骨髄非破壊的同種骨髄移植後に長期寛解を維持している中枢神経浸潤を合併した再発Hodgkinリンパ腫. 臨床血液 53: 1991-1996, 2012
  • 今井陽一: 多発性骨髄腫のゲノム解析と分子病態. 血液内科 64: 167-171, 2012
  • 泉二登志子: 世界の造血器腫瘍の疫学. 日本臨床70 (増刊号2): 9-25, 2012
  • 塩崎宏子, 泉二登志子: 妊娠と鉄欠乏性貧血. 血液内科 65: 749-753, 2012
  • 今井陽一: 多発性骨髄腫のゲノム解析と分子病態. 血液内科 64: 167-171, 2012
2011年

■英文論文

  • Asanuma S, Tanaka J, Sugita J, Kosugi M, Shiratori S, Wakasa K, Shono Y, Shigematsu A, Kondo T, Kobayashi T, Asaka M, Imamura M. Expansion of CD4+ CD25+ regulatory T cells from cord blood CD4+ cells using the common γ-chain cytokines (IL-2 and IL-15) and rapamycin. Ann Hematol 90: 617-624, 2011.
  • Tsutsumi Y, Ito S, Ogasawara R, Kudo K, Tanaka J, Asaka M, Imamura M. HCV virus and lymphoid neoplasms. Adv Hematol. 2011: 717951. Epub 2011 Jul 5.
  • Hayakawa S, Shiratori S, Yamato H, Kameyama T, Kitatsuji C, Kashigi F, Goto S, Kameoka S, Fujikura D, Yamada T, Mizutani T, Kazumata M, Sato M, Tanaka J, Asaka M, Ohba Y, Miyazaki T, Imamura M, *Takaoka A. ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses. Nature Immunol 12: 37-44, 2011.
  • Kobayashi T, Ishida J, Musashi M, Ota S, Yoshida T, Shimizu Y, Chuma M, Kawakami H, Asaka M, Tanaka J, Imamura M, Kobayashi M, Itoh H, Edamatsu H, Sutherland LC, Brachmann RK. p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5. Int J Cancer. 128: 304-318, 2011.
  • Inamoto Y, Miyamura K, Okamoto S, Akiyama H, Iida H, Eto T, Morishima Y, Kawa K, Kikuchi A, Nagatoshi Y, Tanaka J, Ashida T, Hirokawa M, Tsuchida M, Mori S for the Japan Marrow Donor Program. Disease stage stratified effects of cell dose in unrelated bone marrow transplantation for hematological malignancies: A report from Japan Marrow Donor Program. Bone Marrow Transaplant 46:1192-1202, 2011.
  • Onozawa M, Ohmura K, Ibata M, Iwasaki J, Okada K, Kasahara I, Yamaguchi K, Kubota K, Fujisawa S, Shigematsu A, Endo T, Kondo T, Hashino S, Tanaka J, Matsuno Y, Asaka M, Imamura M. The 8p11 myeloproliferative syndrome due to rare FGFR1OP2-FGFR1 fusion. Eur J Haematol 86: 347-349, 2011.
  • Iida M, Fukuda T, Ikegame K, Yoshihara S, Ogawa H, Taniguchi S, Takami A, Abe Y, Hino M, Etou T, Ueda Y, Yujiri T, Matsui T, Okamura A, Tanaka J, Atsuta Y, Kodera Y, Suzuki R. Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan. Inter J Hematol 93:523-531, 2011.
  • Shigematsu A, Tanaka J, Suzuki R, Atsuta Y, Kawase T, Ito YM, Yamashita T, Fukuda T, Kumano K, Iwato K, Yoshiba F, Kanamori H, Kobayashi N, Fukuhara T, Morishima Y, Imamura M. Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia. Int J Hematol 94: 463-471, 2011.
  • Shono Y, Kosugi-Kanaya M, Shiratori S, Sugita J, Fujimoto K, Kondo T, Nishio M, Tanaka J, Imamura M. Donor cell leukemia after umbilical cord blood transplantation: recurrent or de novo? The importance of diagnosis for therapeutic decision making. Int J Hematol 93: 563-565, 2011.
  • Shiratori S, Kondo T, Fujisawa S, Kubota K, Kosugi M, Shono Y, Sugita J, Fujimoto K, Nishio M, Tanaka J, Koike T, Matsuno Y, Matsuno K, Asaka M, Imamura M. c-myc rearrangement in B-cell lymphoblastic lymphoma with the involvement of multiple extranodal lesions. Leuk Lymphoma 52: 716-718, 2011.
  • Arita K, Kondo T, Sugita J, Shigematsu A, Shiratori S, Wakasa K, Yasumoto A, Ibata M, Shono Y, Kikuchi M, Goto H, Takeda Y, Takahata M, Kato N, Nishio M, Ota S, Tanaka J, Imamura M. Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia. Int J Hematol 94: 291-295, 2011.
  • Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H, Shimabe M, Arai S, Nakagawa M, Imai Y, Kumano K, Kumagai K, Kubota, N, Kadowaki T, and Kurokawa M. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. Journal of Experimental Medicine 208: 2403-2416, 2011.
  • Yoshiki Y, Asai T, Ichikawa M, Hangaishi A, Ota S, Imai Y, Takahashi T, and Kurokawa M. A Case of Myeloid Sarcoma with Correlation to JAK2V617F Mutation, Complicated by Myelofibrosis and Secondary Acute Myeloid Leukemia. Internal Medicine 50: 2649-2652, 2011.
  • Nakagawa M, Shimabe M, Watanabe-Okochi N, Arai S, Yoshimi A, Shinohara A, Nishimoto N, Kataoka K, Sato T, Kumano K, Nannya Y, Ichikawa M, Imai Y, and Kurokawa M.  AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors. Blood 118: 6626-6637, 2011.
  • Nishimoto N, Arai S, Ichikawa M, Nakagawa M, Goyama S, Kumano K, Takahashi T, Kamikubo Y, Imai Y, and Kurokawa M. Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through downregulation of p19ARF. Blood 118: 2541-2550, 2011.
  • Yoshizato T, Nannya Y, Yoshiki Y, Nakamura F, Imai Y, Ichikawa M, and Kurokawa M. Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. International Journal of Hematology 93: 400-402, 2011.
  • Nannya Y, Kataoka K, Hangaishi A, Imai Y, Takahashi T, and Kurokawa M. The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. Transplant International 24: 469-476, 2011.
  • Arai S, Yoshimi A, Shimabe A, Ichikawa M, Nakagawa M, Imai Y, Goyama S and Kurokawa M. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 117: 6304-6314, 2011.
  • Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, Arai S, Sato T, Shimabe M, Nakagawa M, Imai Y, Kitamura T, and Kurokawa M. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 117: 3617-3628, 2011.
  • Kobayashi H, Ichikawa M, Hangaishi A, Imai Y, and Kurokawa M. Concurrent development of "Burkitt-like" lymphoma and BCL-2-rearranged low-grade B cell lymphoma sharing the same germinal center origin. International Journal of Hematology 93: 112-117, 2011.
  • Kobayashi CI, Yamamoto G, Hayashi A, Ota S, Imai Y, Fukayama M, and Kurokawa M. Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma. Annals of Hematology 90: 225-226, 2011.
  • Hirai Y, Ainoda Y, Nakamura-Uchiyama F, Umetani K, Totsuka K: Unusual colonoscopic view of Enterobius vermicularis. Intern Med 50: 657, 2011.
  • Kobayashi Y, Sakamaki H, Fujisawa S, Ando K, Yamamoto K, Okada M, Ishizawa K, Nagai T, Miyawaki S, Motoji T, Usui N, Iida S, Taniwaki M, Uoshima N, Seriu T, Ohno R: Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis. Int J Hematol 93: 745-749, 2011
  • Nagai H, Ogura M, Kusumoto S, Takahashi N, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Ohyashiki K, Kosugi H, Matsuda S, Ohnishi K, Omachi K, Hotta T: Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. Eur J Haematol 86: 117-123, 2011
  • Hirai Y, Ainoda Y, Shoji T, Fujita T, Yoshinaga K, Shiseki M, Mori N, Teramura M, Totsuka K, Motoji T: Disseminated Cryptococcosis in a Non-Hodgkin's Lymphoma Patient with Late-Onset Neutropenia Following Rituximab-CHOP Chemotherapy: A Case Report and Literature Review. Mycopathologia 172: 227-232, 2011
  • Yamada O, Ozaki K, Furukawa T, Machida M, Wang YH, Motoji T, Mitsuishi T, Akiyama M, Yamada H, Kawauchi K, Matsuoka R: Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cell Signal 23: 1119-1127, 2011.
  • Shiseki M, Masuda A, Watanabe N, Fujii M, Kimura T, Yoshinaga K, Mori N, Teramura M, Motoji T: Development of diffuse large B-cell lymphoma in a patient with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma: clonal identity between two B-cell neoplasms. Hematol Rep 3: e10, 2011
  • Mori N, Inoue K, Okada M, Motoji T: Absence of Mutations on the SNF5 Gene in Hematological Neoplasms with Chromosome 22 Abnormalities. Acta Haematol 126: 69-75, 2011
  • Tanaka N, Wang YH, Shiseki M, Takanashi M, Motoji T: Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells. Leuk Res 35: 1219-1225, 2011
  • Mori N, Yoshinaga K, Tomita K, Ohwashi M, Kondoh T, Shimura H, Wang YH, Shiseki M, Okada M, Motoji T: Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia. Leuk Res 35: 516-521, 2011
  • Hirai Y: Treatment Options for Gram-Positive and Gram-Negative Bacteria: Focus on Ceftriaxone. Clin Med Rev Ther 3: 215-234, 2011.
  • Nakagawa M, Shimabe M, Watanabe-Okochi N, Arai S, Yoshimi A, Shinohara A et al., AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors., Blood, 118(25), 6626-37, 2011

■和文論文

  • 重松明男, 田中淳司, 今村雅寛: 急性白血病に対する強化移植前処置の意義. 臨床血液52: 667-673, 2011.
  • 三橋健次郎, 志関雅幸, 石山みどり, 近藤年昭, 風間啓至, 安並毅, 岡村隆光, 吉永健太郎, 森直樹, 寺村正尚, 増田昭博, 泉二登志子: 形質細胞性白血病を疑わせるほど末梢血および骨髄に著明な多クローン性形質細胞増生を伴ったAngioimmunoblastic T-cell lymphoma. 臨床血液 52: 563-569, 2011
2010年

■英文論文

  • Kikuchi M, Tanaka J, Kondo T, Hashino S, Kasai M, Kurosawa M, Iwasaki H, Morioka M, Kawamura T, Masauzi N, Fukuhara T, Kakinoki Y, Kobayashi H, Noto S, Asaka M, Imamura M. Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia. Inter J Hematol 92: 481-489, 2010.
  • Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J, Asaka M, Imamura M. Rituximab administration and reactivation of HBV. Hepat Res Treat. 2010;2010: 182067. Epub 2010 Dec 1.
  • Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh K, Ogata M, Kikuchi H, Sagara Y, Uozumi K, Mochizuki M, Tsukasaki K, Saburi Y, Yamamura M, Tanaka J, Moriuchi Y, Hino S, Kamihira S, Yamaguchi K. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 116: 1211-1219, 2010.
  • Sugita J, Tanaka J, Yasumoto A, Hashimoto A, Shiratori S, Wakasa K, Kikuchi M, Shigematsu A, Kondo T, Asaka M, Imamura M. Differential effects of interleukin-12 and interleukin-15 on expansion of NK cell receptor-expressing CD8+ T cells. Ann Hematol 89: 115-120, 2010.
  • Kondo T, Yasumoto A, Arita K, Sugita J, Shigematsu A, Okada K, Takahata M, Onozawa M, Kahata K, Takeda Y, Obara M, Yamamoto S, Endo1 T, Nishio1 M, Sato N, Tanaka J, Hashino1 S, Koike T, Asaka M, Imamura M. Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation. Int J Hematol 91: 310-321, 2010.
  • Takahata M, Hashino S, Okada K, Onozawa M, Kahata K, Sugita J, Shigematsu A, Kondo T, Yamamoto S, Endo T, Nishio M, Ito Y, Tanaka J, Koike T, Asaka M, Imamura M. Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients. Am J Hematol 84: 243-248, 2010.
  • Shigematsu A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Yamaguchi K, Wakasa K, Takahata M, Goto H, Ito S, Takemura R, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M. Increased risk of bacterial infection after engraftment in patients treated with allogeneic bone marrow transplantation following reduced-intensity conditioning regimen. Transpl Infect Dis 12: 412-420, 2010.
  • Imai Y, Shimaoka M, and Kurokawa M. Essential roles of VLA-4 in the hematopoietic system. International Journal of Hematology, 91: 569-575, 2010.
  • Hosoi M, Ichikawa M, Imai Y and Kurokawa M. A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period. International Journal of Hematology 92: 667-668, 2010.
  • Asano H, Imai Y, Ota S, Yamamoto G, Takahashi T, Fukayama M, and Kurokawa M. CD30-positive anaplastic variant diffuse large B cell lymphoma: a rare case presented with cutaneous involvement. International Journal of Hematology 92: 550-552, 2010.
  • Nakazaki K, Hangaishi A, Nakamura F, Hosoi M, Imai Y, Takahashi T, Nannya Y, and Kurokawa M. IgG-associated immune thrombocytopenia in Waldenstrom macroglobulinemia. International Journal of Hematology 92: 360-363, 2010.
  • Kataoka K, Seo S, Sugawara Y, Ota S, Imai Y, Takahashi T, Fukayama M, Kokudo N, and Kurokawa M. Post-transplant lymphoproliferative disorder after adult-to adult living donor liver transplant: case series and review of literature. Leukemia & Lymphoma 51: 1494-1501, 2010.
  • Nishimoto N, Imai Y, Ueda K, Nakagawa M, Shinohara A, Ichikawa M, Nannya Y, and Kurokawa M. T cell acute lymphoblastic leukemia arising from familial platelet disorder. International Journal of Hematology 92: 194-197, 2010.
  • Takahashi T, Hangaishi A, Yamamoto G, Ichikawa M, Imai Y, Kurokawa M. HIV-negative, HHV-8-unrelated primary effusion lymphoma-like lymphoma: report of two cases. American Journal of Hematology 85: 85-87, 2010.
  • Kagoya Y, Hangaishi A, Takahashi T, Imai Y, and Kurokawa M. High-dose dexamethasone therapy for severe thrombocytopenia and neutropenia induced by EBV infectious mononucleosis. International Journal of Hematology 91: 326-327, 2010.
  • Ueda K, Watadani T, Maeda E, Ota S, Kataoka K, Seo S, Kumano K, Hangaishi A, Takahashi T, Imai Y, Ohtomo K, Fukayama M, Nannya Y, and Kurokawa M. Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT. Bone Marrow Trasnplantation 45: 1719-1727, 2010.
  • Ueda K, Nannya Y, Asai T, Yamamoto G, Hangaishi A, Takahasi T, Imai Y, and Kurokawa M. Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma. Journal of Chemotherapy 22: 54-57, 2010.
  • Park EJ, Peixoto A, Imai Y, Goodarzi A, Cheng G, Carman CV, von Andrian UH, and Shimaoka M. Distinct roles for LFA-1 affinity regulation during T cell adhesion, diapedesis, and interstitial migration in lymph nodes. Blood 115: 1572-1581, 2010.
  • Goyama S, Nitta E, Yoshino T, Kako S, Watanabe-Okochi N, Shimabe M, Imai Y, Takahashi K, and Kurokawa M. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. Leukemia 24: 81-88, 2010.
  • Hosoi M, Yamamoto G, Imai Y, and Kurokawa M. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma. Annals of Hematology 89: 207-208, 2010.
  • Masamoto Y, Imai Y, Seo S, Akahane M, and Kurokawa M. A case report of non-traumatic renal artery pseudoaneurysm due to chemotherapy for diffuse large B-cell lymphoma. Annals of Hematology 89: 107-108, 2010.
  • Hirai Y, Ainoda Y, Shoji T, Totsuka K: Ceftriaxone plus gentamicin or ceftriaxone alone for streptococcal endocarditis in Japanese patients as alternative first-line therapies. J Infect Chemother 16: 186-192, 2010
  • Nagai T, Takeuchi J, Dobashi N, Kanakura Y, Taniguchi S, Ezaki K, Nakaseko C, Hiraoka A, Okada M, Miyazaki Y, Motoji T, Higashihara M, Tsukamoto N, Kiyoi H, Nakao S, Shinagawa K, Ohno R, Naoe T, Ohnishi K, Usui N: Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan. Int J Hematol 92: 111-117, 2010
  • Kobayashi S, Teramura M, Arai M, Masuda A, Mizoguchi H, Motoji T: Successful salvage treatment of blastic natural killer cell lymphoma with methotrexate. Int J Hematol 92: 634-637, 2010
  • Shinohara A, Ichikawa M, Ueda K et al., A novel MLL-AF1p/Eps15 fusion variant in therapy-related acute lymphoblastic leukemia, lacking the EH-domains. Leukemia Research、34(2)、e62-3、2010

■和文論文

  • 田中淳司: 慢性骨髄性白血病の治療反応性とorganic cation transporter 1. 血液フロンテイア 20: 45-51, 2010.
  • 田中淳司: 抗腫瘍免疫におけるNK受容体発現細胞の役割. Cytometry Research 20: 11-17, 2010.
  • 今井陽一: 正常核型急性骨髄性白血病の病態解明と治療指針. 血液・腫瘍科 60: 139-142, 2010
  • 縣宗彦, 鮫島勇一, 小田哲朗, 近藤年昭, 石山みどり, 安並毅, 風間啓至, 岡村隆光, 吉永健太郎, 志関雅幸, 森直樹, 山田修, 佐川賢一, 寺村正尚, 泉二登志子: 多発性骨髄腫に対するthalidomide 療法の効果に関与する因子と効果判定時期. 臨床血液51: 189-195, 2010
  • 塩崎宏子, 泉二登志子: 鉄欠乏性貧血の検査と診断. 日内会誌99: 43-49, 2010
  • 泉二登志子: 骨髄増殖性腫瘍の治療. (第72回日本血液学会学術集会教育講演) 臨床血液51: 1428-1436, 2010
  • 岩崎直子, 長原光, 寺村正尚, 小島原典子, 川名正敏, 肥塚直美, 吉岡俊正, 大澤真木子, 白鳥敬子: Breaking bad news教育の有用性とOSCEにおける評価の試み. 医教育 41: 103-109, 2010
  • 三橋健次郎, 松阪諭, 水沼信之, 市村崇, 尾阪将人, 小倉真理子, 篠崎英司, 末永光邦, 陳勁松, 藤本佳也, 齋浦明夫, 山本智理子, 畠清彦: Cetuximab療法により完全切除可能となったFOLFOX療法抵抗性・切除不能直腸癌多発肝転移の1症例, 癌と化学療法 37(11), 2203-2207, 2010
2009年

■英文論文

  • Tanaka J, Sugita J, Asanuma S, Arita K, Shono Y, Kikutchi M, Shiratori S, Wakasa K, Yasumoto A, Shigematu A, Kondo T, Kobayashi T, Asaka M, Imamura M. Increased number of CD16+CD56dim NK cells in peripheral blood mononuclear cells after allogeneic cord blood transplantation. Human Immunol 70: 701-705, 2009.
  • Toubai T, Shono Y, Nishihira J, Ibata M, Suigita J, Kato N, Ohkawara T, Tone S, Lowler K, Ota S, Tanaka J, Asaka M, Reddy P, Imamura M. Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation. Int J Lab Hematol. 31: 161-168, 2009.
  • Tsutsumi Y, Ichiki K, Shiratori S, Kawamura T, Tanaka J, Asaka M, Imamura M, Masauzi N. Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy. Int J Lab Hematol. 31: 468-470, 2009.
  • Tsutsumi Y, Shigematsu A, Hashino S, Tanaka J, Chiba K, Masauzi N, Kobayashi H, Kurosawa M, Iwasaki H, Morioka M, Asaka M, Imamura M. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido. Ann Hematol. 88: 375-377, 2009.
  • Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 15: 679-685, 2009.
  • Toubai T, Shono Y, Tone S, Ibata M, Kato N, Malter C, Lowler KP, Ota S, Tanaka J, Asaka M, Imamura M. Serum soluble tumor necrosis factor-related apoptosis-inducing ligand level after allogeneic hematopoietic cell transplantation. Leuk Lymphoma 50: 844-847, 2009.
  • Onozawa M, Hashino S, Haseyama Y, Hirayama Y, Iizuka S, Ishida T, Kaneda M, Kobayashi H, Kobayashi R, Koda K, Kurosawa M, Masauji N, Matsunaga T, Mori A, Mukai M, Nishio M, Noto S, Ota S, Sakai H, Suzuki N, Takahashi T, Tanaka J, Torimoto Y, Yoshida M, Fukuhara T. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: hokkaido hematology study group. Biol Blood Marrow Transplant 15: 724-729, 2009.
  • Kikuchi M, Okumura F, Tsukiyama T, Watanabe M, Miyajima N, Tanaka J, Imamura M, Hatakeyama S. TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. Biochim Biophys Acta. Molecular Cell Research 1793: 1828-1836, 2009.
  • Tsutsumi Y, Yamamoto Y, Tanaka J, Asaka M, Imamura M, Masauzi N. Prevention of hepatitis B virus reactivation under rituximab therapy. Immunotherapy. 1: 1053-1061, 2009.
  • Imamura M, Tanaka J. Graft-versus-Leukemia Effect of Nonmyeloablative Stem Cell Transplantation. Korean J Intern Med 24: 287-298, 2009.
  • Toubai T, Paczesny S, Shono Y, Tanaka J, Lowler KP, Malter CT, Kasai M, Imamura M. Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Curr Stem Cell Res Ther. 4: 252-259, 2009.
  • Tsutsumi Y, Ito S, Ichiki K, Komatsu Y, Shiratori S, Kawamura T, Kudo K, Shimoyama N, Tanaka J, Asaka M, Imamura M, Masauzi N. Systemic amyloidosis complicated with peliosis. Ann Hematol. 88: 917-920, 2009.
  • Shimabe M, Goyama S, Watanabe-Okochi N, Yoshimi A, Ichikawa M, Imai Y, and Kurokawa M. Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. Oncogene, 10: 4364-4374, 2009.
  • Yoshimi A, Asai T, Maeda D, Hangaishi A, Sakatani T, Takahashi T, Imai Y, Fukayama M, and Kurokawa M. Chronic myelomonocytic leukemia presenting severe uterine hemorrhage due to uterine infiltration of leukemic cells and early-stage endometrial adenocarcinoma. Archives of Gynecology and Obstetrics 280: 1077-1078, 2009.
  • Kataoka K, Ichikawa M, Hangaishi A, Takahashi T, Imai Y, and Kurokawa M. Interstitial pneumonia associated with progression of myelodysplastic syndrome. International Journal of Hematology 89: 718-719, 2009.
  • Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, and Kurokawa M. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. International Journal of Hematology 89: 592-599, 2009.
  • Yoshimi M, Nannya Y, Watanabe T, Asai T, Ichikawa M, Yamamoto G, Kumano K, Hangaishi A, Imai Y, Takahashi T, Chiba S, and Kurokawa M. Acute eosinophilic pneumonia is a non-infectious lung complication after allogeneic hematopoietic stem cell transplantation. International Journal of Hematology 89: 244-248, 2009.
  • Yoshimi A, Nannya Y, Asano D, Yamamoto G, Kumano K, Hangaishi A, Matsui Y, Takahashi T, Imai Y, Kokudo N, and Kurokawa M. Successful haematopoietic stem cell transplantation from an HLA-identical sibling in a patient with aplastic anemia following HLA-haploidentical living-related liver transplantation for fulminant hepatitis. Biology of Blood and Marrow Transplantation 15: 389-390, 2009.
  • Kataoka K, Nannya Y, Hangaishi A, Imai Y, Chiba S, Takahashi T, and Kurokawa M. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 15: 195-204, 2009.
  • Fumiya Miyamura, Shinichi Kato, Hiroko Yamagami, Ken Sato, Miki Sato, Kiriko Terasako, Shun-ichi Kimura, Hideki Nakasone, Satoko Aoki, Shinya Okuda, Rie Yamazaki, Kumi Oshima, Kentaro Yoshinaga, Takakazu Higuchi, Junji Nishida, Toshio Demitsu, Akihiro Kakehashi, Yoshinobu Kanda: Successful treatment of young-onset adult T cell leukemia/lymphoma and preceeding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation. Int J Hematol 90: 397-401,2009
  • Sakamaki H, Ishizawa K, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, Okada M, Ando K, Usui N, Miyawaki S, Utsunomiya A, Uoshima N, Nagai T, Naoe T, Motoji T, Jinnai I, Tanimoto M, Miyazaki Y, Ohnishi K, Iida S, Okamoto S, Seriu T, Ohno R: Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol 89: 332-341, 2009
  • Wang YH, Takanashi M, Tsuji K, Tanaka N, Shiseki M, Mori N, Motoji T: Level of DNA topoisomerase IIα mRNA predicts the treatment response of relapsed acute leukemic patients. Leuk Res 33: 902-907, 2009
  • Ueda K, Yamamoto G, Shinohara A et al., Early onset of acute lymphoblastic leukemia with MLL rearrangement after autologous stem cell transplantation for multiple myeloma., Annals of Hematology, ;88(8), 813-4, 2009

■和文論文

  • 田中淳司: 移植片対白血病(GVL)効果とNKレセプター. 臨床免疫・アレルギー科 52: 86-92, 2009.
  • 今井陽一: 造血と白血病におけるインテグリンの役割, 血液・腫瘍科 59:228-232, 2009
  • 志関雅幸, 泉二登志子: 急性骨髄性白血病における薬剤耐性遺伝子関連蛋白の機序とその対策. 血液フロンティア 20: 23-29, 2009.
  • 泉二登志子: 薬剤耐性のメカニズム. 血液フロンティア20: 17-21, 2009
  • 泉二登志子: 不応性貧血に対する短期大量メチルプレドニゾロンによる免疫療法. 血液フロンティア19: 5-9, 2009
  • 白鳥 聡一, 近藤 健, 若狭 健太郎, 井端 淳, 庄野 雄介, 高畑 むつみ, 重松 明男, 東梅友美,加藤 菜穂子, 太田 秀一, 加畑馨, 武田紫,佐藤典宏, 田中 淳司,浅香 正博,今村 雅寛: 大量AraC療法後の高度の骨髄抑制時に発症した重症MRSA感染症に対して顆粒球輸血が奏功した急性骨髄性白血病. 日本輸血細胞治療学会誌55(1), 37-42, 2009
2008年

■英文論文

  • Sugita J, Tanaka J, Hashimoto A, Shiratori S,Yasumoto A, Wakasa K, Kikuchi M, Shigematsu A, Miura Y, Tsutsumi Y, Kondo T, Asaka M, Imamura M. Influence of conditioning regimens and stem cell sources on donor-type chimerism early after stem cell transplantation. Ann Hematol 87: 1003-1008, 2008.
  • Sugita J, Iwao N, Tanaka J, Kato N, Shiratori S, Wakasa K, Shigematsu A, Toubai T, Takahata M, Kondo T, Asaka M, Imamura M. T cell receptor excision circle (TREC) levels in CD94-expressing CD8 T Cells during graft-versus-host disease. Leukemia Lymphoma 49: 1306-1310, 2008.
  • Sugita J, Tanaka J, Kurosawa M, Fukuhara T, Hashino S, Torimoto E, Koizumi K, Masauji N, Nishimura S, Koda K, Imamura M, Kasai M. Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia (CML) in Japan: a study of the Hokkaido Hematology Study Group. Eur J Haematol. 80: 160-163, 2008.
  • Kaji M, Tanaka J, Sugita J, Kato N, Ibata M, Shono Y, Ota S, Kondo T, Asaka M, Imamura M. Ciprofloxacin inhibits lipopolysaccharide-induced toll-like receptor-4 and 8 expression on human monocytes derived from adult and cord blood. Ann Hematol 87: 229-231, 2008.
  • Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 14: 568-575, 2008.
  • Shiratori S, Yasumoto A, Tanaka J, Shigematsu A, Yamamoto S, Nishio M, Hashino S, Morita R, Takahata M, Onozawa M, Kahata K, Kondo T, Ota S, Wakasa K, Sugita J, Koike T, Asaka M, Kasai M, Imamura M. A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect. Biol Blood Marrow Transplant 14: 817-823, 2008.
  • Imai Y, Park EJ, Peer D, Peixoto A, Cheng G, von Andrian UH, Carman CV, and Shimaoka M. Genetic perturbation of the putative cytoplasmic membrane-proximal salt bridge aberrantly activates α4 integrins. Blood 112: 5007-5015, 2008.
  • Kondo T, Mori A, Darmanin S, Hashino S, Tanaka J, Asaka M. The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive Acute Promyelocytic Leukemia. Haematologica 93: 1414-1416, 2008.
  • Onozawa M, Hashino S, Morita R, Takahata M, Shigematsu A, Kahata K, Kondo T, Tanaka J, Imamura M, Asaka M. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 14: 1226-1230, 2008.
  • Shiratori S, Tsutsumi Y, Kawamura T, Kudo K, Shimoyama N, Masauzi N, Tanaka J, Asaka M, Imamura M. HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution. Int J Hematol 87: 298-302, 2008.
  • Toubai T, Hirate D, Shono Y, Ota S, Ibata M, Mashiko S, Sugita J, Shigematsu A, Miura Y, Kato N, Umehara S, Kahata K, Tsutsumi Y, Iwao N, Toyoshima N, Tanaka J, Asaka M, Imamura M. Chimerism and T-cell receptor repertoire analysis after unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous stem cell transplantation for multiple myeloma. Int J Lab Hematol 30: 75-81, 2008.
  • Imamura S, Uchiyama J, Koshimizu E, Hanai J, Raftopoulou C, Murphey RD, Bayliss PE, Imai Y, Burns CE, Masutomi K, Gagos S, Zon LI, Roberts TM, Kishi S. A non-canonical function of zebrafish telomerase reverse transcriptase is required for developmental hematopoiesis. PLoS ONE 3: e3364, 2008
  • Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, Teramura M, Karasawa M, Arai A, Yonemura Y, Nakao S, Urabe A, Omine M, Ozawa K: PRCA Collaborative Study Group. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 93: 1555-1559, 2008
  • Yamada O, Kawauchi K, Akiyama M, Ozaki K, Motoji T, Adachi T, Aizawa E: Leukemic cells with increased telomerase activity exhibit resistance to imatinib. Leuk Lymphoma 49: 1168-1177, 2008
  • Mori N, Yoshinaga K, Tada M, Wang YH, Shiseki M, Motoji T: Infrequent V617F mutation of the JAK2 gene in myeloid leukemia and its absence in lymphoid malignancies in Japan. Genetics and Molecular Biology 31: 427-430, 2008
  • Yoshinaga K, Mori N, Wang YH, Tomita K, Shiseki M, Motoji T: JAK2 V617F mutation is rare in idiopathic erythrocytosis : a difference from polycythemia vera. Int J Hematol 88: 82-87, 2008
  • Kitagawa Y, Sameshima Y, Shiozaki H, Ogawa S, Masuda A, Mori S, Teramura M, Masuda M, Kameoka S, Motoji T: Isolated granulocytic sarcoma of the small intestine successfully treated with chemotherapy and bone marrow transplantation. Int J Hematol 87: 410-413, 2008
  • Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A et al., Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation., International Journal of Hematology, 87(3), 310-8, 2008
  • 14)Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A et al., Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation., American Journal of Hematology, 83(6), 472-6, 2008

■和文論文

  • 田中淳司: GVHDとGVL制御におけるNK受容体発現細胞の役割. 臨床血液49: 598-606, 2008.
  • 重松明男, 杉田純一, 山本聡, 小野澤真宏, 遠藤知之, 加畑馨, 白鳥聡一, 若狭健太郎, 高畑むつみ, 近藤健, 田中淳司, 西尾充史, 橋野聡, 小池隆夫, 浅香正博, 今村雅寛 : 骨髄非破壊的前処置と骨髄破壊的前処置による同種骨髄移植後感染症の比較. 無菌生物 38: 27-32, 2008
  • 今井陽一, 黒川峰夫: 急性骨髄性白血病発症の分子機構. 血液フロンティア18: 21-27, 2008
  • 白鳥 聡一, 近藤 健, 久保田 佳奈子, 若狭 健太郎, 井端 淳, 庄野 雄介, 高畑 むつみ, 重松 明男, 加藤 菜穂子, 太田 秀一, 田中 淳司, 松野 吉宏, 浅香 正博, 今村 雅寛: Rituximab投与によりCD20の陰性化が認められたCD20陽性・Cyclin D1陽性多発性骨髄腫. 臨床血液46: 1536-1540, 2008
  • 吉永健太郎, 志関雅幸, 近藤年昭, 森直樹, 寺村正尚, 泉二登志子: 中枢神経原発悪性リンパ腫に大量メソトレキサート療法が有効であった1例. 老造血器疾患研会誌17: 29-32, 2008